Quarterly Report · 10-Q
Larimar Therapeutics, Inc.
LRMRNASDAQEQUITYCurrent
Quarterly Report
Company context
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Current securities
As-filed source
As filedOpen full document ↗